| Abstract | The restless legs syndrome is a neurological disorder characterised by the urge to move the extremities associated with paraesthesias, which are partially or totally relieved by movement, a worsening of symptoms at rest and in the evening or at night and, as a consequence, sleep disturbances. Restless legs syndrome is common and affects 1-10% of the population. The aetiology of restless legs syndrome is unknown, but, beside genetic factors, the dopaminergic system may play a crucial role. Current treatment strategies are not curative, but may nevertheless produce an effective and lasting relief of symptoms. Evidence-based and clinical guidelines identify dopamine agonists as a first-line treatment for daily restless legs symptoms, and such substances are in the process of registration for this indication. In May 2005, the first dopamine agonist, ropinirole, was approved by the FDA. This review discusses treatment studies of dopamine agonists in patients with restless legs syndrome and focuses on long-term treatment with dopamine agonists. |
| Authors | Stephany Fulda, Thomas C Wetter
(Affiliation: Max Planck Institute of Psychiatry, Kraepelinstrasse 10, D-80804 Munich, Germany.)
|
| Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 6
Issue 15
Pg. 2655-66
(Dec 2005)
ISSN: 1744-7666 England |
| PMID | 16316304
(Publication Type: Journal Article, Review)
|
| Chemical References |
|
| Topics |
- Dopamine Agonists
(therapeutic use)
- Humans
- Restless Legs Syndrome
(drug therapy, metabolism)
|
